
Leukemia Trialist | Assist. Prof. @MCG_AUG @GACancerCenter| @UNCHemeOnc trained | Former Osler Resident @OslerResidency | Forever South Carolina Gamecock @UofSC
Joined November 2023
- Tweets156
- Following181
- Followers173
- Likes214
Daniel Peters retweeted
How I Treat: MRD testing to personalize allogeneic HCT for adults with AML ashpublications.org/blood/ar…
Daniel Peters retweeted
We are entering a new frontier in AML ➡️The Paradigm study now out in @NEJM showing improved EFS in younger non-fav. risk AML Tx with Aza/Ven vs. Intensive chemo. Huge congrats to Amir Fathi & all authors for this incredibly important study & milestone. nejm.org/doi/full/10.1056/NE…
Daniel Peters retweeted
1/5 For a decade, decitabine has been assumed superior to azacitidine in TP53-mutant AML based on deeper molecular clearance. We tested that assumption in 652 patients across 15 centers #COMMAND_consortium Thread 🧵 #leusm #AML #TP53 teapawt.net/intent/tweet?url=https… @LeukemiaJnl @Dr_AmerZeidan @Anand_88_Patel @Dr_RoryShallis @ShyamPatelMDPhD @yu_hung_wang @vamkota @yasminabaza1 @AlexColtoff @AyaOncologist @CharlieFoucar @MRLitzow @MKD_BMT @hemant_murthy @ChenyuLinMD et al.
Daniel Peters retweeted
Out in @BloodPortfolio ! OPTI-AML,Ph 2 randomized study of Aza+28D (AV28) vs 14D(AV14) Ven for first 2 cycles in AML pts >=60 yrs. This study generated a LOT of discussion so here are all the relevant details about this first prospective Ven dose optimization study ! 🧵
ashpublications.org/blood/ar…
Daniel Peters retweeted
PRISM Risk Model, the new IPSS-M for AML pts Tx w/ Aza/Ven finally out in print in @JCO_ASCO. PRISM incorporates 17 clinical & genomic variables into a prognostic risk model that is better than ELN-2024.
ascopubs.org/doi/pdfdirect/1…
Daniel Peters retweeted
Excited to share our study on immune interactions in extramedullary (lung) acute myeloid leukemia (AML) out today at @NatImmunol !! Acute respiratory failure frequently occurs in AML due to leukemia infiltration of the lungs. The question is why and what can we do to suppress it. @VarvaraParask in the lab started this work by mapping AML:stromal and AML:immune cell interactions using scRNA-Seq and Visium/Xenium @10xGenomics spatial tools.
nature.com/articles/s41590-0…
Daniel Peters retweeted
Can’t wait to finally see the OPTI-AML data presented by @beatalleukemia at @EHA_Hematology on Thursday. An immense amount of effort by the Beat AML team @bcutd_research with highly impactful results 👇.
Excited to head to #EHA2026 where I will present results of the much anticipated OPTI-AML study on behalf of the BEAT AML investigators @bcutd_research Master Trial ,Thurs Jun 11-see details 👇🏾. Hope to see many of you there ! In the words of ABBA seeing as we are in Stockholm.
Daniel Peters retweeted
💣 AZA + VEN doesn’t fail—execution does.
Day 21 marrow decides everything.
Shorten VEN, not AZA.
Don’t wait for perfect counts.
Here’s how we induce AML in 2026 👇
Please let us know your approach.
#AML #HemeTwitter
Dr Fun + G
Daniel Peters retweeted
🧬 HMA + Venetoclax in Younger AML — 50 Pearls (2026 Meta-analysis)
📌 Credits: Perrone et al., Cancer 2026
⸻
🔥 Paradigm shift: VEN+HMA moving beyond “unfit” → selected younger AML
🧬 Mechanism: BCL-2 inhibition → restores apoptosis → deep responses
👨⚕️ Population: Median age ~54 yrs (<70 included)
📊 Total data: 8 studies | 429 pts (RCT + phase 2 + real-world)
🎯 CR/CRi pooled: 66%
🧪 MRD negativity: ~69% → deep remission signal
📈 1-year OS: ~75% → > historical (~62%)
📉 1-year EFS: ~59% (low heterogeneity)
🧠 Key: EFS consistency strongest signal across studies
🔁 Bridge to transplant: ~66% proceed to HSCT
🧬 Decitabine trend > azacitidine (EFS/OS signal)
⚖️ Compared to IC: similar or better early outcomes in selected pts
🚫 Not replacing IC in favorable-risk AML
⚠️ More promising in adverse-risk AML
🧬 MRD-driven strategy emerging
🔄 Potential chemo-sparing induction approach
🏥 Less toxicity vs IC → fewer infections, cytopenias
📉 Lower hospitalization burden (outpatient feasible)
🧠 QoL advantage (less ICU, less long stays)
💰 Likely cost-effective (data extrapolated)
📊 CR heterogeneity high (I² ~89%)
🧪 MRD variability due to methods/timing
📉 OS heterogeneity low → robust outcome
🧬 Biology-driven response (TP53, FLT3, NPM1 matter)
🧪 ELN 2024 integrates VEN-based approaches
⚠️ Fitness > age → key selection principle
🧬 Favorable-risk AML → IC still gold standard
⚠️ PARADIGM excluded key subtypes → limits generalizability
🧬 Hybrid strategies (VEN+HMA → IC consolidation) used
🔁 Continuous therapy needed if no HSCT
🧠 MRD-negative pts → may defer transplant (investigational)
📉 Relapse-free survival data inconsistent
🧬 Younger pts (≤45 yrs) → better EFS
📊 CR range wide: ~40%–89% across studies
📉 US real-world outcomes lower vs trials
🌍 Geography variation (China vs US vs EU cohorts)
🧪 Venetoclax duration impact unclear
⚠️ Dosing heterogeneity across studies
🧬 Transplant intent differs across trials
📊 HSCT rates vary widely (33%–100%)
🧠 Suggests strategy tailoring (not uniform)
🧬 VEN+FLAG-IDA / VEN+IC also emerging competitors
📉 Toxicity still present (cytopenias, infections)
🧪 Need standardized MRD assessment
📊 No strong randomized superiority vs IC yet
🧬 Strong rationale for phase 3 trials
🧠 Key concept: induction ≠ necessarily intensive chemo
🔬 VEN+HMA = “biologic induction” approach
📌 Best role: bridge-to-transplant strategy
⚠️ Patient selection remains critical
🧬 Future: biomarker-driven allocation
📊 Meta-analysis limitation: heterogeneity + mixed designs
🧠 Clinical takeaway: powerful option in non-favorable risk younger AML
⸻
#AML #Venetoclax #HMA #Leukemia #BMT #Transplant #Hematology #Oncology
Daniel Peters retweeted
🚨Out in @BCD_AACR today! "Models, Models, Everywhere: But Which One Should Guide Care?" our In the Spotlight piece with @CLachowiez is now online! We review therapy-specific prognostic models including the newly pulished model by Drekolias et al for #AML treated with #venetoclax-based regimens & chart the path forward.
shorturl.at/Je1VF
Daniel Peters retweeted
Azacytidine, our fantastic hypomethylating agent, used for treatment of MDS and AML, was discovered in 1964, and then fell into oblivion. Almost 40 years later it was FDA approved as the first effective MDS treatment.
A 🧵about an unusual revival:
Daniel Peters retweeted
Divergent disease names, criteria, and even diagnoses (e.g., AML vs. MDS). It's time to end the division! This paper outlines a clear path forward: bridging gaps through evidence-based consensus to rally around the next WHO edition (WHO6).
link.springer.com/article/10…
Daniel Peters retweeted
One of my favorite things to write with two colleagues from whom I’ve learned a great deal. @MSKCancerCenter
ashpublications.org/blood/ar…
Daniel Peters retweeted
Hot off the press-> New @BloodCancerUtd Beat AML Analysis @BloodAdvances analyzing clinical outcomes of NPM1m or KMT2Ar AML in pts >60 y/o. This is an important historical reference prior to use of Menin inhibitors. @beatalleukemia @UNC_Lineberger
ashpublications.org/bloodadv…
Daniel Peters retweeted
🧬 Why Cyclophosphamide (PTCy) is given on D+3 (±D+4) — NOT D+2 post allo-SCT
🧵 Thread (mechanism-based, guideline-driven):
🕒 Day 0 = graft infusion
➡️ Donor T cells enter host
➡️ Antigen recognition starts but most alloreactive T cells are NOT yet dividing
🔄 Day +1 to +2
❌ Alloreactive T cells still in early activation phase
❌ Many NOT in S-phase
❌ Cyclophosphamide would MISS key pathogenic clones
🧪 Cyclophosphamide = cell-cycle dependent cytotoxicity
➡️ Kills rapidly dividing T cells
➡️ Needs cells in active DNA synthesis
📈 Peak alloreactive T-cell proliferation = Day +3
✅ Pathogenic GVHD-causing T cells enter rapid cycling
✅ Maximum susceptibility to cyclophosphamide
🎯 Day +3 (± Day +4) = SWEET SPOT
🔥 Deletes alloreactive donor T cells
🛡️ Preserves:
•🧫 Hematopoietic stem cells (↑ ALDH expression)
•🧑⚕️ Regulatory T cells (ALDH-high, slower cycling)
•🦠 Pathogen-specific memory T cells
❌ Why NOT Day +2?
⚠️ Too early
⚠️ Incomplete deletion of alloreactive clones
⚠️ → Higher risk of acute GVHD
❌ Why NOT later (D+5 or beyond)?
⚠️ Alloreactive T cells exit peak proliferation
⚠️ Less cyclophosphamide sensitivity
⚠️ Loss of selectivity → ↑ GVHD, ↑ toxicity
⚖️ Clinical balance achieved at D+3:
✔️ GVHD prevention
✔️ Engraftment preserved
✔️ GVL effect maintained
✔️ Immune reconstitution spared
📌 Bottom line:
🧠 PTCy timing is biologically timed to T-cell kinetics — not arbitrary
⏱️ D+3 targets the enemy when it’s most vulnerable
#PTCy #AlloSCT #GVHD #BMT #TransplantImmunology #Hematology #KFSHRC #SOHO_KSA #ESH_Emirates_Hematology_Society
Daniel Peters retweeted
Maintenance therapy after alloHCT in high-risk #AML has long been a grey area. This study provides a strong scientific rationale for post-alloHCT maintenance with menin inhibitors, enhancing GVL. #menin_inhibitors @BloodPortfolio #weekend_review
doi.org/10.1182/blood.202502…
Daniel Peters retweeted
so.... viola .... 🪄
We built a clinic-ready algorithm: Combine genomic signature (biTET2 or SRSF2+TET2 co-mut) + BM monocyte frequency → more accurately predicts progression in OM-CMML vs relying on monocyte count alone.
SF3B1, multi-TP53 are MDS categories likely to have borderline monocytosis.. don't overcall them as CMML
Integrate genomics into CMML diagnosis to avoid misclassification.
Daniel Peters retweeted
Excellent chapter in the #ASH25_Education_book and lecture on
🧬 Post-alloHCT maintenance in AML @Mark_J_levis from @HopkinsMedicine
🔹 Strongest evidence in FLT3-ITD AML
🔹 Benefit driven by MRD status + immune synergy (IL-15, GvL)
🔹 Not all targets are equal: FLT3 > Menin (emerging) > IDH (selective)
🔹 Parenteral AZA → negative randomizsed data
🔹 Oral AZA (CC-486) → no proven OS/RFS benefit post-HCT
Take-home:
👉 MRD-guided, biology-directed maintenance should be the goal.
📚 Key trials & data
• SORMAIN – JCO 2020
• Xuan et al. – JCO 2021
• MORPHO – Blood 2023
• FLT3–IL-15 immune synergy – Nat Med 2018
• Menin inhibitors in KMT2A AML – NEJM 2023
Oran et al. Blood 2020
• AMADEUS trial – CC-486 post-HCT (results awaited / no signal yet)
• VIAL-T – AZA/VEN post-HCT (terminated)
#AML #AlloHCT #ASH25 @ASH_hematology @BloodPortfolio @ASHEducationbook @OncoAlert @AML_Hub @ASTCT
Daniel Peters retweeted
🎥Learn about the key findings from the phase II PARADIGM trial of Aza + Ven vs conventional induction chemotherapy in fit patients with ND AML, presented at #ASH25 with our expert interview – featuring Amir Fathi.
Watch here: loom.ly/8P5x1uI
#AMLsm #leusm @MassGeneralNews


























